Industry
Biotechnology
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 29, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 10:06 am
Portfolio Pulse from Benzinga Newsdesk
March 26, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
March 15, 2024 | 2:51 pm
Portfolio Pulse from Avi Kapoor
March 11, 2024 | 5:41 pm
Portfolio Pulse from Avi Kapoor
March 11, 2024 | 2:37 pm
Portfolio Pulse from Erica Kollmann
March 11, 2024 | 2:28 pm
Portfolio Pulse from Benzinga Newsdesk
March 05, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
February 28, 2024 | 4:22 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.